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Abstract
Most cases of a predisposition to venous thrombosis are caused by resistance to activated protein C, associated in
95%ofcaseswiththeFactorVLeidenallele(FVLorR506Q).Severalrecentstudiesreportafurtherincreasedriskof
thrombosisbyanassociationbetweentheABallelesoftheABObloodgroupandFactorVLeiden.Thepresentstudy
investigated this association with deep vein thrombosis (DVT) in individuals treated at the Hemocentro de
Pernambuco in northeastern Brazil. A case-control comparison showed a significant risk of thrombosis in the pres-
ence of Factor V Leiden (OR = 10.1), which was approximately doubled when the AB alleles of the ABO blood group
were present as well (OR = 22.3). These results confirm that the increased risk of deep vein thrombosis in the com-
bined presence of AB alleles and Factor V Leiden is also applicable to the Brazilian population suggesting that ABO
blood group typing should be routinely added to FVL in studies involving thrombosis.
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Deep vein thrombosis (DVT) is one of the main clini-
cal manifestations of venous thromboembolism (VTE).
DVT is a multi-factorial disorder caused by genetic and/or
acquired abnormalities of the hemostatic mechanism, re-
sulting in hypercoagulation (Dahlbäck, 2003; Dahlbäck
and Villoutrex, 2003). Hereditary thrombophilia is respon-
sible for most cases of predisposition to VTE and the great-
est prevalence is of a resistance to activated protein C
(Svensson and Dahlbäck, 1994), caused in most cases by a
pointmutationinthegeneofthecoagulationfactorV(FV),
known as Factor V Leiden (FVL), FV: R506Q or FV:
G1691A. (Bertina et al., 1994). FV is a plasma glyco-
protein of 330 kDa, formed by 2196 amino acids and coded
by a gene with 25 exons located in chromosome region
1q21-25 (Wang et al., 1988; Cripe et al., 1992). In its acti-
vated form (FVa), it participates in the prothrombinase
complex of the coagulation cascade as an essential co-
factor to factor Xa in thrombin genesis. FV is also a
proteolytic target for activated protein C (APC), which ex-
ercises its anti-coagulant function by deactivating it. The
deactivated FV and protein S act as co-factors of APC, de-
activating the factor VIII (FVIII) molecule (Dahlbäck and
Villoutrex, 2003). The R506Q mutation occurs in exon 10
oftheFVgeneandischaracterizedbyaGAtransitionat
nucleotide1691,whichresultsinachangefromArginineto
Glutamine (Arg  Gln) at position 506 in the amino acid
sequence (Bertina et al., 1994). The main consequence of
this mutation is the loss of one of the cleavage sites, which
makesFVapartiallyresistanttotheproteolyticdegradation
of APC. This flaw in the anticoagulation mechanism
mainly results in high FVIII and trombin levels, thereby in-
creasing the risk of VTE due to the installation of a state of
hypercoagulability (Franco and Reitsma, 2001).
The AB alleles of the ABO blood group, high FVIII
levels and von Willebrand factor (vWF) have been associ-
atedtoariskofvenousthrombosis(Jicketal.,1969;Koster
etal.,1995;Tiradoetal.,2005).Anumberofreportsreveal
that individuals with the AB genotype have higher FVIII
and vWF levels than those with the O genotype (Preston
and Barr, 1964; Orstavick et al., 1985; Gill et al., 1987;
Kamphuisen et al., 1998). Studies have also reported that
theassociationbetweentheR506QalleleandABallelesin-
creases the risk of thrombosis (Robert et al., 2000; Morelli
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Short Communicationet al., 2005; Biron-Adréani et al., 2006; Ohira et al., 2007).
The present study investigated the relationship between
DVT and the association of AB genotypes and the R506Q
allele in the population of the state of Pernambuco in north-
eastern Brazil.
Sixty-five patients participated in the study (47 fe-
males and 18 males) with a mean age of 34 years (range
6-67years)andnofamilialrelationshipstooneanother.All
patientshadahistoryofDVTandweretreatedattheoutpa-
tient clinic of the Fundação HEMOPE (Pernambuco, Bra-
zil) between 2001 and 2006. An additional 51 individuals
from the same state and with no history of DVT were se-
lected for the control group, which was paired for gender
and age group and had no family relationships to one an-
other or to the patients. All samples were collected follow-
ing the informed consent of the participants.
Peripheral venous blood samples were collected in a
sterile vacutainer tube containing EDTA as the anticoagu-
lant.GenomicDNAwasextractedandpurifiedfromleuko-
cytes using the GFX genomic DNA purification kit
(Amershan Pharmacia Biotech), following the manufac-
turer’sinstructions.GenotypingoftheABOsystemandde-
tectionoftheR506Qalleleinthepatientsandcontrolswere
performed through real-time polymerase chain reac-
tion/allelic discrimination assay using the ABI PRISM
7000SequenceDetectionSystem(SDS).Fortheamplifica-
tion reactions, the Taqman Universal PCR Master Mix
(Applied Biosystems, Foster City, CA) set of reagents was
used together with a set of primers and specific probes for
the differentiation between the O and A or B genotypes and
differentiation between wild alleles and R506Q, designed
and synthesized by the Assays-by-Design service (Part
Number 4331349) from the sequences of interest sent to
Applied Biosystems. In the text and Tables, the genotype
designation O refers to absence of any A or B alleles at the
ABO locus and AB refers to any of the following: AA, AO,
AB, BB, or BO.
Followingamplification,thefragmentswerediscrim-
inated by fluorescent data analysis through the software
program (version 1.1) on the ABI PRISM 7000 SDS equip-
ment.Statisticalanalysiswasperformedbyunivariateanal-
ysis, using the Bioestat 4.0 program (Ayres et al., 2005).
Confidencelimitsweresetat95%andexactpvaluesdeter-
mined using Pearson’s Chi square.
The frequencies of patients and controls, ABO and
FVL genotypes and Odds Ratios of increased risk of DVT
are displayed in Table 1.
We have assumed that all or the majority of FVL (+)
individuals were heterozygotes and carried only a single
mutant allele, which is a reasonable assumption given the
allele frequency of between 0.02-0.05 seen in many popu-
lations. In the patient group, 29.3% had the R506Q allele,
whereasonly3.9%inthecontrolgroup.Thisledtoahighly
significant risk of DVT (OR = 10.1; 95%CI = 2.23-45.9;
p = 0.0004) which was higher than that described in the
study by Morelli et al. (2005), which was 7.9. This risk was
increased further in individuals with the AB/FVL(+) geno-
type combination (OR = 22.3; 95%CI = 2.68-185.7;
p = 0.0002) These results are compatible with all previous
investigations on the combined additive contribution of
ABOandFVLgenotypestoDVT.Theresultsofpreviously
published studies are summarized in Table 2. All studies
demonstrate the added risk of AB alleles which approxi-
mately doubles the risk imparted by FVL. The differences
in ORs between studies are probably explicable on small
sample sizes and ethnic or chance differences in observed
ABO and FVL allele frequencies. The exact mechanism
throughwhichtheABallelesinfluencetheriskofthrombo-
sis is not yet well clarified. However, evidence suggests
that it could be explained by the effect of the ABO locus on
the rise in plasma levels of FVIII (Morelli et al., 2005),
likely due to a lower catabolism of the vWF (Gill et al.,
1987). The presence of oligosaccharides with A, B and O
structuresinthehumanvWFmoleculesupportthishypoth-
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Table 1 - Combined risk of thrombosis for ABO and FVL genotypes.
Genotypes N. of patients (%)n=6 5 N .o fcontrols (%)n=5 1 O Rexact p value CI (95%)
O 18 (27.7) 22 (43.1) 1*
AB 47 (72.3) 29 (56.9) 1.98 0.91-4.30
p = 0.42
FVL (-) 46 (70.7) 49 (96.0) 1*
FVL (+) 19 (29.2) 2 (3.9) 10.11 2.23-45.88
p = 0.0004
O and FVL (–) 16 (24.6) 21 (41.2) 1*
O and FVL (+) 2 (3.1) 1 (1.96) 2.62 0.21-31.5
AB and FVL (–) 30 (46.1) 28 (54.9) 1.40 0.61-3.22
AB and FVL (+) 17 (26.2) 1 (1.96) 22.3 2.68-185.7
p = .0002
FVL (+) = assumed heterozygotes ; FVL (–) = wild type homozygotes.*Reference category. OR = odds ratio. CI (95%) = 95% confidence interval.esis(Sodetzetal.,1979;Matsuietal.,1992).Inindividuals
with the FVL who have the AB genotype, the weak deacti-
vation of FVIII in combination with high levels of this fac-
tor through the influence of the ABO genotype are thought
toresultinanexponentialincreaseintheriskofdeveloping
VTE (Morelli et al., 2005; Váradi et al., 1996).
The present study confirms that the association of a
combined increased risk of AB alleles and FVL to deep
vein thrombosis is also applicable to the population of
North Eastern Brazil. We propose that ABO genotyping
should be carried out routinely in combination with FVL to
evaluate risk for DVT. It would also be of great interest to
study whether ABO alleles also have an additive affect in
other situations, such as spontaneous abortion or reduced
menopausal age, where FVL has also been claimed to play
a role.
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